JP Morgan Chase
ACRV icon

JP Morgan Chase’s Acrivon Therapeutics ACRV Stock Holding History

JP Morgan Chase’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$823 Sell
638
-16,226
-96% -$28.3K ﹤0.01% 7144
2025
Q4 		$40.6K Buy
16,864
+15,123
+869% +$32.9K ﹤0.01% 6311
2025
Q3 		$3.15K Buy
1,741
+323
+23% +$454 ﹤0.01% 6841
2025
Q2 		$1.69K Sell
1,418
-7,061
-83% -$9.69K ﹤0.01% 6559
2025
Q1 		$17.2K Sell
8,479
-17,330
-67% -$93.3K ﹤0.01% 6193
2024
Q4 		$155K Sell
25,809
-8,182
-24% -$59.5K ﹤0.01% 5583
2024
Q3 		$238K Buy
33,991
+28,748
+548% +$227K ﹤0.01% 5327
2024
Q2 		$30.4K Buy
5,243
+284
+6% +$2.29K ﹤0.01% 6030
2024
Q1 		$35.5K Sell
4,959
-28,384
-85% -$132K ﹤0.01% 6062
2023
Q4 		$164K Buy
33,343
+6,771
+25% +$35.8K ﹤0.01% 5496
2023
Q3 		$254K Buy
26,572
+19,645
+284% +$227K ﹤0.01% 4918
2023
Q2 		$89.8K Buy
6,927
+297
+4% +$3.6K ﹤0.01% 5514
2023
Q1 		$84K Buy
+6,630
New +$111K ﹤0.01% 5501

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's ACRV Position: Q1 2026 in Review

JP Morgan Chase reduced its Acrivon Therapeutics (ACRV) stake by 96% in Q1 2026, selling an estimated $28.3K and leaving 638 shares worth $823. The position accounts for ﹤0.01% of the portfolio, ranked #7144.

JP Morgan Chase first reported a position in ACRV in Q1 2023 and has held it in 13 quarters since. The position peaked at $254K in Q3 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • JP Morgan Chase held 638 shares of Acrivon Therapeutics worth $823 as of Q1 2026.
  • JP Morgan Chase sold 16,226 Acrivon Therapeutics shares in Q1 2026, an estimated $28.3K.
  • Acrivon Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7144 holding.
  • JP Morgan Chase first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • JP Morgan Chase's Acrivon Therapeutics position peaked at $254K in Q3 2023.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.